These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

5707 related articles for article (PubMed ID: 3806572)

  • 1. New cyanomorpholinyl byproduct of doxorubicin reductive alkylation.
    Acton EM; Tong GL; Taylor DL; Filppi JA; Wolgemuth RL
    J Med Chem; 1986 Jul; 29(7):1225-30. PubMed ID: 3806572
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intensely potent morpholinyl anthracyclines.
    Acton EM; Tong GL; Mosher CW; Wolgemuth RL
    J Med Chem; 1984 May; 27(5):638-45. PubMed ID: 6716401
    [TBL] [Abstract][Full Text] [Related]  

  • 3. N-(2-hydroxyethyl)doxorubicin from hydrolysis of 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin.
    Acton EM; Tong GL; Smith TH; Taylor DL; Streeter DG; Peters JH; Gordon GR; Filppi JA; Wolgemuth RL; Giuliani FC
    J Med Chem; 1986 Oct; 29(10):2120-2. PubMed ID: 3761328
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparative cytotoxicities of various morpholinyl anthracyclines.
    Streeter DG; Taylor DL; Acton EM; Peters JH
    Cancer Chemother Pharmacol; 1985; 14(2):160-4. PubMed ID: 3971481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhanced antitumor properties of 3'-(4-morpholinyl) and 3'-(4-methoxy-1-piperidinyl) derivatives of 3'-deaminodaunorubicin.
    Mosher CW; Wu HY; Fujiwara AN; Acton EM
    J Med Chem; 1982 Jan; 25(1):18-24. PubMed ID: 7086816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA topoisomerase II-mediated interaction of doxorubicin and daunorubicin congeners with DNA.
    Bodley A; Liu LF; Israel M; Seshadri R; Koseki Y; Giuliani FC; Kirschenbaum S; Silber R; Potmesil M
    Cancer Res; 1989 Nov; 49(21):5969-78. PubMed ID: 2551497
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of 3'-deamino-3'-(3-cyano-4-morpholinyl)doxorubicin and doxorubicin on the survival, DNA integrity, and nucleolar morphology of human leukemia cells in vitro.
    Wassermann K; Zwelling LA; Mullins TD; Silberman LE; Andersson BS; Bakic M; Acton EM; Newman RA
    Cancer Res; 1986 Aug; 46(8):4041-6. PubMed ID: 3731072
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Models of preclinical studies of anthracyclines].
    Fizames C
    Pathol Biol (Paris); 1987 Jan; 35(1):41-8. PubMed ID: 3550611
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Doxorubicin and the alkylating anthracycline 3'-deamino-3'-(3-cyano-4-morpholinyl) doxorubicin: comparative in vitro potency against leukemia and bone marrow cells.
    Beckman RA; McFall PJ; Sikic BI; Smith SD
    J Natl Cancer Inst; 1988 May; 80(5):361-5. PubMed ID: 3357201
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anti-tumor activity of daunorubicin linked to poly-L-aspartic acid.
    Zunino F; Giuliani F; Savi G; Dasdia T; Gambetta R
    Int J Cancer; 1982 Oct; 30(4):465-70. PubMed ID: 7141741
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Preparation and antitumor activity of new mitomycin A analogues.
    Sami SM; Iyengar BS; Remers WA; Bradner WT
    J Med Chem; 1987 Jan; 30(1):168-73. PubMed ID: 3806593
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calmodulin inhibitor trifluoperazine selectively enhances cytotoxic effects of strong vs weak DNA binding antitumor drugs in doxorubicin-resistant P388 mouse leukemia cells.
    Ganapathi R; Grabowski D; Schmidt H; Seshadri R; Israel M
    Biochem Biophys Res Commun; 1985 Sep; 131(2):912-9. PubMed ID: 2932108
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Activity of SC33428, a novel bishydrazone-bridged derivative of 4-demethoxydaunorubicin, against experimental tumors in mice.
    Dawson KM
    Cancer Res; 1983 Jun; 43(6):2880-3. PubMed ID: 6573953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dissociation of antitumor potency from anthracycline cardiotoxicity in a doxorubicin analog.
    Sikic BI; Ehsan MN; Harker WG; Friend NF; Brown BW; Newman RA; Hacker MP; Acton EM
    Science; 1985 Jun; 228(4707):1544-6. PubMed ID: 4012308
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Characterization of the DNA-DNA cross-linking activity of 3'-(3-cyano-4-morpholinyl)-3'-deaminoadriamycin.
    Jesson MI; Johnston JB; Robotham E; Begleiter A
    Cancer Res; 1989 Dec; 49(24 Pt 1):7031-6. PubMed ID: 2531036
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytostatic activity of daunorubicin analogs containing daunosamine as furanoside.
    Kuszmann J; Medgyes G; Dvortsák P; Tory K
    Arzneimittelforschung; 1986 May; 36(5):786-9. PubMed ID: 3730013
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Markedly reduced levels of anthracycline-induced DNA strand breaks in resistant P388 leukemia cells and isolated nuclei.
    Capranico G; Riva A; Tinelli S; Dasdia T; Zunino F
    Cancer Res; 1987 Jul; 47(14):3752-6. PubMed ID: 3474061
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity comparison of mitomycin C and mitomycin A analogues (review).
    Bradner WT; Remers WA; Vyas DM
    Anticancer Res; 1989; 9(4):1095-9. PubMed ID: 2510580
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitumor effect of selected daunorubicin derivatives in mice with P 388 leukemia.
    Kuśnierczyk H; Rak J; Radzikowski C
    Arch Immunol Ther Exp (Warsz); 1986; 34(3):259-62. PubMed ID: 3592929
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Total chemical synthesis and antitumor evaluation of 4-demethoxy-10,10-dimethyldaunomycin.
    Alexander J; Khanna I; Lednicer D; Mitscher LA; Veysoglu T; Wielogorski Z; Wolgemuth RL
    J Med Chem; 1984 Oct; 27(10):1343-7. PubMed ID: 6481770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 286.